The ICC recommends to subclassify MDS/AML along the lines of other AML, into 4 subgroups defined by mutated TP53, myelodysplasia-related gene mutations, myelodysplasia-related cytogenetic abnormalities, or no specific genetic features (NOS); further research is needed to determine the clinical significance of subgrouping MDS/AML and the relationship of these subgroups to their overt AML counterparts with ≥20% blasts [22]. This evidence concerns the gene TP53 and myelodysplastic syndrome.